Literature DB >> 19467802

Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy.

Lawrence Koutcher1, Nancy Lee, Michael Zelefsky, Kelvin Chan, Gilad Cohen, David Pfister, Dennis Kraus, Suzanne Wolden.   

Abstract

PURPOSE: To determine survival rates of patients with locally recurrent nasopharynx cancer (LRNPC) treated with modern therapeutic modalities. METHODS AND MATERIALS: From July 1996 to March 2008, 29 patients were reirradiated for LRNPC. Thirteen patients received combined-modality treatment (CMT), consisting of external beam radiotherapy (EBRT) followed by intracavitary brachytherapy, whereas 16 received EBRT alone. The median age was 50 years, 59% were male, 38% were Asian, 69% had World Health Organization Class III histology, and 86% were treated for their first recurrence. Nine, 6, 8, and 6 patients had recurrent Stage I, II, III, and IV disease, respectively. Patients in the EBRT-alone group had more advanced disease. Median time to reirradiation was 3.9 years. In total, 93% underwent imaging with positron emission tomography and/or magnetic resonance imaging before reirradiation, 83% received intensity-modulated radiotherapy, and 93% received chemotherapy, which was platinum-based in 85% of cases.
RESULTS: The median follow-up for all patients was 45 months and for surviving patients was 54 months. Five-year actuarial local control, event-free survival, and overall survival rates were 52%, 44%, and 60%, respectively. No difference was observed between patients treated with EBRT or CMT. Overall survival was superior in patients who achieved local control (p = 0.0003). The incidence of late Grade > or =3 events in patients re-treated with EBRT alone was significantly increased compared with those receiving CMT (73% vs. 8%; p = 0.005).
CONCLUSIONS: In this modern reirradiation series of patients with LRNPC, favorable overall survival compared with historical series was achieved. Patients treated with CMT experienced significantly fewer severe late effects compared with those treated with EBRT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19467802     DOI: 10.1016/j.ijrobp.2009.01.055

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.

Authors:  Victor H F Lee; Dora L W Kwong; To-Wai Leung; Sherry C Y Ng; Ka-On Lam; Chi-Chung Tong; Chun-Kin Sze
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-10-13       Impact factor: 2.503

2.  Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma. Treatment results and locoregional recurrence.

Authors:  J L-Y Chen; Y-S Huang; S-H Kuo; Y-F Chen; R-L Hong; J-Y Ko; P-J Lou; C-L Tsai; W-Y Chen; C-W Wang
Journal:  Strahlenther Onkol       Date:  2013-10-27       Impact factor: 3.621

3.  Assessment of the radiotherapy effect for nasopharyngeal cancer using plasma surface-enhanced Raman spectroscopy technology.

Authors:  Qiong Wu; Sufang Qiu; Yun Yu; Weiwei Chen; Huijing Lin; Duo Lin; Shangyuan Feng; Rong Chen
Journal:  Biomed Opt Express       Date:  2018-06-27       Impact factor: 3.732

4.  A nomogram to predict loco-regional control after re-irradiation for head and neck cancer.

Authors:  Nadeem Riaz; Julian C Hong; Eric J Sherman; Luc Morris; Matthew Fury; Ian Ganly; Tony J C Wang; Weji Shi; Suzanne L Wolden; Andrew Jackson; Richard J Wong; Zhigang Zhang; Shyam D Rao; Nancy Y Lee
Journal:  Radiother Oncol       Date:  2014-06-30       Impact factor: 6.280

5.  Cavernous sinus metastases treated with gamma knifeTM stereotactic radiosurgery.

Authors:  Amit Ayer; Brandi R Page; John T Lucas; J Daniel Bourland; Eric R Oliver; Stephen B Tatter; Thomas L Ellis; Michael D Chan
Journal:  J Radiosurg SBRT       Date:  2014

6.  Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives.

Authors:  Sharon Shuxian Poh; Yoke Lim Soong; Kiattisa Sommat; Chwee Ming Lim; Kam Weng Fong; Terence Wk Tan; Melvin Lk Chua; Fu Qiang Wang; Jing Hu; Joseph Ts Wee
Journal:  Cancer Commun (Lond)       Date:  2021-05-06

7.  Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines.

Authors:  R Simo; M Robinson; M Lei; A Sibtain; S Hickey
Journal:  J Laryngol Otol       Date:  2016-05       Impact factor: 1.469

8.  Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.

Authors:  T Finazzi; T Rordorf; K Ikenberg; G F Huber; M Guckenberger; H I Garcia Schueler
Journal:  BMC Cancer       Date:  2018-04-06       Impact factor: 4.430

9.  Effectiveness and toxicities of intensity-modulated radiotherapy for patients with locally recurrent nasopharyngeal carcinoma.

Authors:  Hai-yan Chen; Xiu-mei Ma; Ming Ye; Yan-li Hou; Hua-Ying Xie; Yong-rui Bai
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

10.  Dose distributions of an ¹⁹²Ir brachytherapy source in different media.

Authors:  C H Wu; Y J Liao; Y W Hsueh Liu; S K Hung; M S Lee; S M Hsu
Journal:  Biomed Res Int       Date:  2014-04-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.